

# Our pipeline

PROJECT	DESCRIPTION	INDICATIONS	PARTNERS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	FILING	REGIONS
<b>Delgocitinib</b> <sup>1</sup> LP0133	Topical pan-JAK inhibitor	Chronic hand eczema	JT						Global
		Palmoplantar Pustulosis							
<b>Calcipotriol</b> LP0053	Calcipotriene and betamethasone dipropionate foam	Plaque Psoriasis	LEO Pharma						China <sup>2</sup>
<b>Tralokinumab</b> <sup>3</sup> LP0162	Anti-IL-13 monoclonal antibody	Atopic Dermatitis (Pediatrics)	AstraZeneca						Global
		Atopic Dermatitis (AD on hands)							Global
<b>Temtokibart</b> LP0145	Anti-IL-22RA1 monoclonal antibody	Atopic Dermatitis	argenx						Global
<b>IL-1RAcP</b> LP0189	Anti-IL-1RAcP monoclonal antibody	Inflammatory skin diseases	MorphoSys						Global
<b>STAT6</b> <sup>4</sup>	Oral program	Inflammatory diseases	Gilead						Global
<b>Topical STAT6</b> <sup>5</sup> LP0208	Topical program	Inflammatory skin diseases							Global

<sup>1</sup> Approved in the EU, UK, Switzerland and the UAE for Chronic Hand Eczema

<sup>2</sup> Approved in e.g. the EU and U.S. for plaque psoriasis.

<sup>3</sup> Approved in e.g. the EU and U.S. for atopic dermatitis in adults and adolescents.

<sup>4</sup> Partnership announced 11 January 2025: Gilead controls the global rights to oral STAT6 program and are in full control of the clinical development. LEO Pharma will have the option to co-commercialize oral programs for dermatology ex-US.

<sup>5</sup> LEO Pharma holds an exclusive license from Gilead for STAT6 topical products.